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the HIV Prevention Trials Network 071 (PopART) Trial in 
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Background. There have been concerns about reduced adherence and human immunodeficiency virus (HIV) virological sup-
pression (VS) among clinically well people initiating antiretroviral therapy (ART) with high pre-ART CD4 cell counts. We compared 
virological outcomes by pre-ART CD4 count, where universal ART initiation was provided in the HIV Prevention Trials Network 
071 (PopART) trial in South Africa prior to routine national and international implementation.
Methods. This prospective cohort study included adults initiating ART at facilities providing universal ART since January 2014. 
VS (<400 copies/mL), confirmed virological failure (VF) (2 consecutive viral loads >1000 copies/mL), and viral rebound were com-
pared between participants in strata of baseline CD4 cell count.
Results. The sample included 1901 participants. VS was ≥94% among participants with baseline CD4 count ≥500 cells/µL at all 
6-month intervals to 30 months. The risk of an elevated viral load (≥400 copies/mL) was independently lower among participants 
with baseline CD4 count ≥500 cells/µL (3.3%) compared to those with CD4 count 200–499 cells/µL (9.2%) between months 18 and 
30 (adjusted relative risk, 0.30 [95% confidence interval, .12–.74]; P = .010). The incidence rate of VF was 7.0, 2.0, and 0.5 per 100 
person-years among participants with baseline CD4 count <200, 200–499, and ≥500 cells/µL, respectively (P < .0001). VF was inde-
pendently lower among participants with baseline CD4 count ≥500 cells/µL (adjusted hazard ratio [aHR], 0.23; P = .045) and 3-fold 
higher among those with baseline CD4 count <200 cells/µL (aHR, 3.49; P < .0001).
Conclusions. Despite previous concerns, participants initiating ART with CD4 counts ≥500 cells/µL had very good virological 
outcomes, being better than those with CD4 counts 200–499 cells/µL.
clinical Trials Registration. NCT01900977.
Keywords. HIV/AIDS; early antiretroviral treatment; virological outcomes; baseline CD4 cell count; HPTN 071 (PopART) Trial.
Effective virological suppression (VS) among people living with 
human immunodeficiency virus (PLHIV) receiving antiretrovi-
ral therapy (ART) is essential for both individual benefit and to 
reduce human immunodeficiency virus (HIV) transmission [1, 2]. 
Although there has been progress toward the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) target of 90% of people 
receiving ART achieving VS by 2020 [3], a number of challenges 
remain [4]. Concerns have been expressed that ART adherence 
and VS may be suboptimal among those starting ART with higher 
CD4 cell counts as they may be asymptomatic [5, 6]. Indeed, higher 
CD4 count at ART initiation has previously been associated with 
increased viremia and virological failure (VF) [7–9].
In 2015, the World Health Organization (WHO) recom-
mended ART initiation for all PLHIV [10]. This recommenda-
tion was adopted by South Africa in September 2016, with prior 
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CD4 count initiation thresholds being 350 cells/µL and 500 cells/
µL, consistent with international recommendations. As part of 
the HIV Prevention Trials Network (HPTN) 071 (PopART) 
cluster-randomized trial, all adults living with HIV have been 
able to access ART at 3 facilities in South Africa since January 
2014 [11], almost 3 years prior to the country’s clinical guide-
lines revision.
There are very few published data of virological outcomes 
of PLHIV initiating ART with baseline CD4 count >500 cells/
µL in sub-Saharan Africa [12, 13]. Implementation research is 
needed to assess the effectiveness of the expanded HIV treat-
ment strategy and the provision of ART for HIV prevention [5, 
6]. The HPTN 071 (PopART) trial provided a unique opportu-
nity to examine outcomes of people initiating ART irrespective 
of CD4 count in sub-Saharan Africa prior to routine implemen-
tation of the revised WHO clinical guidelines. In view of pre-
vious concerns regarding virological response during universal 
test and treatment for HIV, this study aimed to quantify viro-
logical outcomes of people initiating ART early (baseline CD4 
count ≥500 cells/µL) and to compare these virological outcomes 
to people initiating ART with lower CD4 counts in the Western 
Cape Province, South Africa.
METHODS
Setting
A prospective cohort study was conducted among adults initi-
ating ART at 3 public primary healthcare clinics randomly allo-
cated to the full intervention arm of the HPTN 071 (PopART) 
cluster-randomized trial in South Africa. A full description of 
the trial design is published elsewhere [11, 14]. Communities 
surrounding the clinics received household delivery of a combi-
nation HIV prevention package, including HIV education and 
HIV rapid testing in the home by community HIV care pro-
viders, referral to the clinics, and active linkage to ART. Study 
clinics offered ART regardless of CD4 count for all adults liv-
ing with HIV. Provincial guidelines’ CD4 count ART initiation 
thresholds during the study period were ≤350 cells/µL until 
January 2015 and ≤500 cells/µL thereafter [15].
Adults aged ≥18 years initiating ART between January 2014 
and November 2015 with available baseline CD4 count mea-
surements and at least 1 on-treatment viral load (VL) were 
included in analyses. Clients already receiving ART who trans-
ferred into the clinics were excluded. Database closure was 31 
January 2017.
Outcomes
The outcomes were:
 1. Proportions of participants with measured VL being elevated 
(≥400 copies/mL) at 6-month intervals after starting ART to 
a maximum of 30 months.
 2. Cumulative probability of confirmed VF (2 consecutive VLs 
of >1000 copies/mL) after starting ART.
 3. Cumulative probability of viral rebound (VL ≥400 copies/
mL) after initial VS, among participants achieving initial VS 
who had at least 1 repeat VL >30 days after initial VS.
VS was defined as VL <400 copies/mL. The principal exposure 
was baseline CD4 count, defined as the most recent CD4 count 
routinely performed within 6 months before starting ART. CD4 
counts were categorized as <200, 200–499, and ≥500 cells/μL. 
Early ART was defined as a baseline CD4 count of ≥500 cells/
μL. The category 200–499 cells/μL was the reference category 
for all regression analyses.
All participants received standard care and routine follow-up 
as per Department of Health (DOH) ART guidelines except-
ing that individuals starting ART outside of DOH guidelines 
signed informed consent. All participants received standard of 
care adherence support provided by clinic-based counselors 
complemented by support from community HIV care pro-
viders who were scheduled to see clients a minimum of annu-
ally. Guidelines recommended that VL testing be performed 
4–6 months after starting ART and at month 12, then annually; 
when elevated (≥400 copies/mL), the VL was to be repeated 
2–6 months later.
Data Collection and Analysis
Clinical data were extracted from sites’ electronic ART patient 
databases, electronic tuberculosis (TB) registers, and National 
Health Laboratory Services databases. Baseline characteristics 
of adults included and excluded from analyses due to absent 
VL data within the primary exposure categories of inter-
est (baseline CD4 count ≥500 cells/μL and 200–499 cells/μL) 
were compared using Wilcoxon rank-sum or Pearson χ2 tests 
as appropriate. Baseline characteristics of the included study 
sample were compared across strata of baseline CD4 cell count. 
To estimate relative risks of an elevated VL, crude and adjusted 
modified Poisson regression with generalized estimating equa-
tions to account for clustering by individual was used, with an 
exchangeable correlation structure [16]. Separate models were 
constructed for the first year of ART and for the period after the 
first year to 30 months. All models were controlled for time on 
ART and healthcare facility. The Wald test was used for global 
hypothesis tests of the overall effect of multilevel categorical 
predictor variables.
Kaplan-Meier estimates were used to analyze time to con-
firmed VF after starting ART, time to viral rebound after ini-
tial VS, and time from starting ART to initial VS. Time was 
measured from the date of starting ART (or date of first VS for 
viral rebound analyses) to either the event of interest otherwise 
censored at the most recent available VL result or 24 months 
following entry, whichever occurred last. The log-rank test was 
used to compare exposure categories. Cox proportional hazards 
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regression was used for crude and adjusted analyses of predic-
tors of confirmed VF and viral rebound. To account for clus-
tering of observations within facilities, stratified Cox regression 
was conducted allowing the baseline hazard for each facility to 
vary. Proportional hazards assumptions were confirmed to be 
not violated using scaled Schoenfeld residuals.
For the main regression analyses, multiple imputation of 
missing covariate values using chained equations was con-
ducted assuming missing covariate values were missing at 
random [17, 18], using 10 imputed datasets. The proportions 
of missing covariate values that were imputed were low: base-
line WHO clinical stage, 1.0%; choice of first nucleoside reverse 
transcriptase inhibitor drug, 1.1%; choice of nonnucleoside 
reverse transcriptase inhibitor (NNRTI) drug, 1.1%. Baseline 
covariates eligible for inclusion in all multivariable models were 
age, sex, WHO stage, pregnancy, concurrent TB, initial ART 
regimen, prior ART exposure, and year of starting ART.
As a sensitivity analysis to assess any effect due to miss-
ing outcome data, missing VL results were also imputed with 
fully conditional specification for both included individuals 
and those excluded from the main analyses due to absent VL 
data [19]. VL data were imputed as binary values (suppressed/
elevated) according to the guidelines’ recommended testing 
intervals (6, 12, and 24 months after starting ART) for the dura-
tion that individuals remained in care at the site during fol-
low-up. Multivariable regression of factors associated with an 
elevated VL was then repeated on the expanded dataset using 
the same set of predictor variables included in the main analy-
ses. Statistical analyses were performed with Stata version 15.1. 
Ethical approval was provided by the Stellenbosch University 
Health Research Ethics Committee.
RESULTS
During the enrollment period, 2864 individuals started 
receiving ART, of whom 1901 met inclusion criteria and were 
included in analyses (Supplementary Figure 1). The propor-
tion of individuals excluded due to absent VL data did not 
differ by baseline CD4 count strata (Supplementary Table 1). 
No statistically significant differences in baseline character-
istics were found between excluded and included individuals 
within baseline CD4 count strata, except that excluded indi-
viduals had a higher proportion who initiated ART in 2015 
(Supplementary Table 2).
Table 1. Baseline Characteristics of Study Participants According to Strata of Baseline CD4 Cell Count (N = 1901)
Characteristic
 
Baseline CD4 Count Category, Cells/μL All Participants
<200 200–499 ≥500  
No. included (row %) 477 (25.1) 1024 (53.9) 400 (21.0) 1901 (100)
Baseline CD4 count, cells/μL, median (IQR) 113 (61–158) 341 (268–407) 623 (552.9–766) 331 (199–471)
Age, y, median (IQR) 33.7 (29.3–39.7) 31.7 (26.4–37.8) 31.0 (26.2–37.9) 32.1 (27.1–38.7)
Age category, y     
 18–24 43 (9.0) 187 (19.3) 80 (20.0) 310 (16.3)
 25–34 222 (46.5) 488 (47.7) 189 (47.3) 899 (47.3)
 35–49 187 (39.2) 268 (26.2) 99 (24.8) 554 (29.1)
 ≥50 25 (5.2) 81 (7.9) 32 (8.0) 138 (7.3)
Male sex 201 (42.1) 313 (30.6) 82 (20.5) 596 (31.4)
Baseline WHO stage (n = 1883)     
 I/II 310 (65.8) 887 (87.4) 364 (91.7) 1561 (82.9)
 III 133 (28.2) 115 (11.3) 30 (7.6) 278 (14.8)
 IV 28 (5.9) 13 (1.3) 3 (0.8) 44 (2.3)
Pregnant 12 (2.5) 57 (5.6) 33 (8.3) 102 (5.4)
Baseline TB treatment 112 (23.5) 75 (7.3) 20 (5.0) 207 (10.9)
First NRTI in ART regimen (n = 1880)     
 Tenofovir 452 (96.6) 1002 (98.8) 396 (99.5) 1850 (98.4)
 Zidovudine 7 (1.5) 7 (0.7) 2 (0.5) 16 (0.9)
 Stavudine 9 (1.9) 5 (0.5) 0 (0) 14 (0.7)
NNRTI in ART regimen (n = 1881)     
 Efavirenz 457 (98.1) 1005 (98.7) 395 (99.5) 1857 (98.7)
 Nevirapine 9 (1.9) 13 (1.3) 2 (0.5) 24 (1.3)
Previous ART exposure for >3 mo 25 (5.2) 15 (1.5) 4 (1.0) 44 (2.3)
Year of starting ART     
 2014 125 (26.2) 312 (30.5) 141 (35.3) 578 (30.4)
 2015 352 (73.8) 712 (69.5) 259 (64.8) 1323 (69.6)
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; TB, tuberculosis; 
WHO, World Health Organization.
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Among included participants, the median baseline CD4 
count was 331 cells/µL (Table 1). The distribution of partic-
ipants by baseline CD4 count strata was 477 (25.1%), 1024 
(53.9%), and 400 (21.0%) with CD4 count <200, 200–499, and 
≥500 cells/µL, respectively. Participants who initiated early ART 
(baseline CD4 count ≥500 cells/µL) had less advanced baseline 
WHO clinical stage disease, were less likely to be receiving con-
comitant TB treatment, and had an appreciably lower propor-
tion of males than participants in lower CD4 count strata. Those 
with baseline CD4 count <200 cells/µL had a higher proportion 
with prior ART exposure.
The proportions having available VL results among those 
remaining in care were high (80%–100%) at all 6-monthly time-
points after initiating ART; these did not differ by baseline CD4 
count category excepting at 18 months (which was not a rec-
ommended time-point for VL testing according to the clinical 
guidelines) (Supplementary Table 3).
Time to initial VS was shorter with increasing baseline CD4 
count: After 12 months, the cumulative probability of VS was 
79.7%, 82.9%, and 85.8% among participants with baseline CD4 
counts <200, 200–499, and ≥500 cells/µL, respectively (log-rank 
P for trend = .005).
Between 6 and 30  months of ART, VS was higher accord-
ing to baseline CD4 count strata: 82.2% (653/794), 93.3% 
(1635/1752), and 95.2% (634/666) among participants with 
baseline CD4 counts <200, 200–499, and ≥500 cells/µL, respec-
tively (P for trend < .0001). VS was ≥94% at all 6-monthly time-
points among participants with baseline CD4 count ≥500 cells/
µL up to 30 months. Illustrated in Figure 1, participants with 
baseline CD4 count <200 cells/µL had substantially increased 
proportions with elevated VLs, whereas participants with base-
line CD4 count ≥500 cells/µL had lower proportions with ele-
vated VLs between months 18 and 30, compared to participants 
with baseline CD4 count 200–499 cells/µL.
Table 2 shows predictors of an elevated VL. During the first 
year of ART, there was no difference in the risk of an elevated 
VL between participants with baseline CD4 count ≥500 cells/
µL vs 200–499 cells/µL. However, between months 18 and 30, 
participants with baseline CD4 count ≥500 cells/µL had a sub-
stantially reduced risk of an elevated VL compared to partici-
pants with baseline CD4 count 200–499 cells/µL (3.3% vs 9.2%, 
respectively; P =  .020), with a 70% reduction in multivariable 
analyses (adjusted relative risk [aRR],  0.30 [95% confidence 
interval {CI}, .12–.74]; P  =  .010). Participants with baseline 
CD4 count <200 cells/µL had a considerably increased risk of 
an elevated VL during both the first year on ART (16.1%) and 
during months 18–30 (23.4%).
Sixty (3.2%) participants developed confirmed VF during 
follow-up, with an incidence rate of 2.9 cases per 100 per-
son-years (PY) (95% CI, 2.2–3.7). VF was inversely related 
to baseline CD4 count. The incidence rate of VF was 7.0, 2.0, 
and 0.5 cases per 100 PY among participants with baseline 
CD4 counts of <200, 200–499, and ≥500 cells/µL, respec-
tively (P  <  .0001). After 24  months, the cumulative proba-
bility of VF was 19.8%, 5.3%, and 0.7% among participants 
with baseline CD4 counts of <200, 200–499, and ≥500 cells/
µL, respectively (Figure 2). The cumulative probability of VF 
among participants with baseline CD4 count >500 cells/µL 
remained unchanged between months 7 and 24. In multivari-
able analyses, compared to participants with baseline CD4 
count 200–499 cells/µL, those with baseline CD4 count ≥500 
cells/µL had a 77% reduced risk of VF (adjusted hazard ratio 
[aHR],  0.23 [95% CI, .05–.97]; P  =  .045), while those with 
baseline CD4 <200 cells/µL had a 3-fold increased risk of VF 
(aHR, 3.49; P < .0001) (Table 3).
A total of 1082 participants achieved VS and had a subse-
quent VL measurement. Amongst these, 81 (7.5%) developed 
viral rebound at a rate of 7.4 cases per 100 PY. In multivari-
able analyses, participants with baseline CD4 count <200 cells/
µL had a significantly increased risk of viral rebound, but there 
was no difference between participants initiating early ART 
compared to those with baseline CD4 count 200–499 cells/µL 
(Supplementary Table 4; Supplementary Figure 2).
In the sensitivity analysis including imputed VL data for 
those with missing VLs and including individuals excluded 
from main analyses due to absent VL data, the association 
between a reduced risk of an elevated VL among those with 
baseline CD4 count ≥500 cells/µL compared to 200–499 
cells/µL remained apparent during months 18–30 (aRR,  0.35; 
P = .027; Supplementary Table 5).
DISCUSSION
Individuals with baseline CD4 count ≥500 cells/µL had excellent 
virological outcomes; VS and VF were better in this group com-
pared to participants with baseline CD4 count 200–499 cells/µL, 
Figure 1. Proportion of participants with elevated viral load (>400 copies/mL) 
according to baseline CD4 cell count strata and time on antiretroviral therapy (ART). 
Vertical bars are 95% confidence intervals.
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and viral rebound was equivalent. This suggests that, despite 
individuals with CD4 count ≥500 cells/µL being less likely to 
have HIV-related symptoms, expansion of programs to encour-
age early ART initiation across sub-Saharan Africa will support 
achieving the UNAIDS third “90-90-90” target of VS by 2020. 
The results suggest that adherence is good among those initi-
ating ART with CD4 counts ≥500 cells/µL, which aligns with 
recently reported adherence outcomes from another universal 
test and treat trial [20], and is encouraging for the scale-up of 
ART for all PLHIV.
Previous research of virological outcomes has primarily been 
conducted among people with baseline CD4 count <500 cells/
µL, and has shown mixed results. Most studies found that low 
baseline CD4 count predicted viremia and VF [21–24]; how-
ever, a Ugandan study found that baseline CD4 count ≥250 
cells/µL independently predicted persistent viremia [7].
Higher baseline CD4 count has also predicted poorer viro-
logical outcomes in 2 previous studies that included participants 
with baseline CD4 counts >500 cells/µL [8, 9]. In contrast, VS 
was similar up to 6–12 months of ART in the early vs deferred 
ART arms of the Strategic Timing of Antiretroviral Therapy 
and TEMPRANO trials [25, 26] and a recent Brazilian obser-
vational study [27].
Reasons for increased VF among those with low baseline 
CD4 count include low CD4 count being a marker of lower 
HIV-specific host immune responses and higher baseline VL, 
which are predictors of subsequent viremia and VF [28–31]. 
HIV drug resistance may also contribute to VF in this group 
that had a higher prevalence of previous ART exposure. Drug 
resistance is increasing in sub-Saharan Africa [32, 33]; thus, 
expanding drug resistance testing (including pre-ART screen-
ing) is important considering the historic use of NNRTI single 
agents for prevention of mother-to-child transmission, the 
anticipated rollout of tenofovir-based preexposure prophylaxis, 
and the transition to dolutegravir-based regimens [34].
Potential mechanisms for improved virological outcomes with 
baseline CD4 count ≥500 cells/µL include greater host immune 
responses, lower baseline VL, fewer comorbidities, less concomi-
tant medication, and fewer drug–drug interactions. Importantly, 
the results mitigate concerns that people in southern Africa who 
initiate ART during earlier stages of HIV infection when not 
clinically unwell will have reduced adherence [5, 6].
It is possible that previous studies that found less advanced 
immunosuppression to be associated with poorer virological 
response had lower proportions of participants having prior 
ART exposure (thus possible drug resistance) among those with 
lower baseline CD4 counts compared to our study, with sub-
sequently better virological response in this group compared 
to our study, explaining differences in results to our study. Our 
study is among the first to measure longer-term virological out-
comes in a prospective cohort study among people initiating 
ART with baseline CD4 count >500 cells/µL in high-HIV-prev-
alence settings.
Increased investment is being made in South Africa to ini-
tiate 2 million people on ART over 2  years [35]. This study 
suggests that 20% of these may have baseline CD4 counts ≥500 
cells/µL, and that their virological outcomes are potentially 
favorable. Nevertheless, one-quarter of participants had base-
line CD4 counts <200 cells/µL; therefore, efforts to identify and 
link people to ART early in the disease course remain essential, 
along with screening and prophylaxis for cryptococcal disease 
and TB and diagnosis and treatment of severe bacterial infec-
tions. The median baseline CD4 count in this cohort (331 cells/
μL) was, however, substantially higher than historical levels 
[36], promisingly suggesting that the rollout of ART regardless 
of CD4 count will lead to increases in baseline CD4 count and 
associated improved clinical outcomes.
Study strengths include that data were part of a high-qual-
ity routine dataset, strengthened by prospective data qual-
ity improvement during the HPTN 071 (PopART) trial. 
Participant follow-up continued for up to 24–30  months. 
There were high rates of completeness in key data fields with 
only a small proportion (6.6%) of eligible clients excluded 
due to missing baseline CD4 counts. VL test completion of 
those in care was high (>80%), which is notable as routine VL 
monitoring in other southern African countries is frequently 
unavailable [37]. Clinic activities were closely aligned to 
standard care during the study period, supporting generaliz-
ability of findings. Study limitations include that a relatively 
large number of people were excluded from analyses due to 
absent VL data. Most of these individuals discontinued fol-
low-up during the initial months of treatment prior to initial 
VL testing, as commonly occurs in southern Africa [38]. The 
proportions excluded due to absent VL data did not differ 
Figure 2. Kaplan-Meier failure estimates of confirmed virological failure (2 con-
secutive viral loads >1000 copies/mL) according to baseline CD4 count strata after 
starting antiretroviral therapy (ART).
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by baseline CD4 count strata, and baseline characteristics of 
excluded and included individuals did not differ significantly 
within baseline CD4 count strata, excepting for year of ART 
initiation, which was not associated with any outcomes. Also, 
the sensitivity analysis including imputed VL data for those 
excluded due to absent VLs showed similar results to the main 
analysis, so it is not likely that sampling bias altered outcome 
comparisons between baseline CD4 count categories. VL at 
ART initiation may be associated with on-treatment virolog-
ical outcomes; however, baseline VL data were not included 
as baseline VLs were not performed as part of the study and 
are not performed routinely in South Africa. Although partic-
ipants with baseline CD4 count ≥500 cells/µL were less likely 
to be receiving concomitant TB treatment and had a lower 
proportion of males than participants in lower CD4 count 
strata, these differences are unlikely to have biased outcome 
measures as neither factor was associated with any of the out-
comes in multivariable analyses.
CONCLUSIONS
The HPTN 071 (PopART) trial has provided a unique opportu-
nity to examine virological outcomes during universal test and 
treatment for HIV prior to routine implementation. Participants 
initiating ART with CD4 count ≥500 cells/µL had better (or at 
least equivalent) VS and reduced VF compared to participants 
initiating ART with CD4 counts 200–499 cells/µL. These find-
ings provide support for and are encouraging for universal ART 
implementation in Africa. Expansion of programs targeting 
Table 3. Predictors of Confirmed Virological Failure Among Participants Initiating Antiretroviral Therapy
Characteristic Virologic Failure, no./No. (%) PY Rate per 100 PY (95% CI)
Crude Analysis Multivariable Analysisa
HR (95% CI) P Value Adjusted HR (95% CI) P Value
Total sample 60/1901 (3.2) 2103.6 2.9 (2.2–3.7) … … … …
CD4 count, cells/μL      < .0001   < .0001
 <200 35/477 (7.3) 499.6 7.0 (5.0–9.8) 4.10 (2.41–7.00) < .0001 3.49 (2.00–6.14) < .0001
 200–499 23/1024 (2.2) 1163.2 2.0 (1.3–3.0) Ref …  Ref …  
 ≥500 2/400 (0.5) 440.8 0.5 (.1–1.8) 0.20 (.05–.84) .028 0.23 (.05–.97) .045
Age, y      .10   .29
 18–24 6/310 (1.9) 345.4 1.7 (.8–3.8) 0.54 (.23–1.26)  0.75 (.32–1.78)  
 25–49 53/1453 (3.6) 1613.8 3.3 (2.5–4.3) Ref …  Ref …  
 ≥50 1/138 (0.7) 144.4 0.69 (.1–4.9) 0.22 (.03–1.60)  0.22 (.30–1.65)  
Sex          
 Female 37/1305 (2.8) 1456.7 2.5 (1.8–3.5) Ref …  Ref …  
 Male 23/596 (3.9) 651.9 3.5 (2.3–5.3) 1.40 (.84–2.37) .196 0.85 (.49–1.48) .569
Baseline WHO stage      .0001 …  .085
 I/II 36/1561 (2.3) 1736.1 2.1 (1.5–2.9) Ref …  Ref …  
 III 19/278 (6.8) 298.4 6.4 (4.1–10.0) 3.07 (1.76–5.35)  2.10 (1.07–4.10)  
 IV 5/44 (11.4) 52.9 9.5 (3.9–22.7) 3.48 (1.35–8.98)  2.00 (.70–5.71)  
Pregnancy          
 Nonpregnant women 36/1203 (3.0) 1341.1 2.7 (1.9–3.7) Ref …  … …  
 Pregnant woman 1/102 (1.0) 110.6 0.9 (.1–6.4) 0.33 (.05–2.41) .275 … …  
Baseline TB treatment          
 No 47/1694 (2.8) 1886.0 2.5 (1.9–3.3) Ref …  Ref …  
 Yes 13/207 (6.3) 217.7 6.0 (3.5–10.3) 2.46 (1.33–4.54) .004 0.97 (.45–2.05) .927
Regimen first NRTI      .71    
 Tenofovir 58/1850 (3.1) 2043.7 2.8 (2.2–3.7) Ref …  … …  
 Zidovudine 1/16 (6.3) 22.9 4.4 (.6–31.0) 1.28 (.17–9.26)  … …  
 Stavudine 1/14 (7.1) 16.7 6.0 (.8–42.6) 2.15 (.30–15.6)  … …  
Regimen NNRTI          
 Efavirenz 59/1857 (3.2) 2062.5 2.9 (2.2–3.7) Ref …  … …  
 Nevirapine 1/24 (4.2) 23.2 4.3 (.9–30.6) 1.72 (.24–12.47) .591 … …  
Previous ART exposure          
 No 58/1857 (3.1) 2058.9 2.8 (2.2–3.6) Ref …  … …  
 Yes 2/44 (4.6) 44.7 4.5 (1.1–17.9) 1.64 (.40–6.74) .491 … …  
Year of starting ART          
 2014 31/578 (5.4) 893.5 3.5 (2.4–4.9) Ref …  … …  
 2015 29/1323 (2.2) 1210.1 2.4 (1.7–3.4) 1.20 (.66–2.12) .540 … …  
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PY, 
person-years; TB, tuberculosis; WHO, World Health Organization.
aThe multivariable model included baseline CD4 cell count category, age, sex, baseline WHO stage, and concomitant TB at baseline. Crude and adjusted models were stratified by site.
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early ART initiation are important to reach the UNAIDS sec-
ond and third “90-90-90” elements of ART coverage and VS. 
Further research assessing methods to improve VS among those 
starting ART with CD4 counts <200 cells/µL is warranted, 
and increased efforts to reduce early ART discontinuation are 
needed.
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